CHMMF (Chimeric Therapeutics) Interest Expense: $-0.20 Mil (TTM As of Dec. 2025)


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics Interest Expense?

Chimeric Therapeutics CHMMF -96.67% 13 Interest Expense is $-0.20 Mil as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chimeric Therapeutics's interest expense for the six months ended in Dec. 2025 was $ -0.12 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.20 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chimeric Therapeutics's Operating Income for the six months ended in Dec. 2025 was $ -2.50 Mil. Chimeric Therapeutics's Interest Expense for the six months ended in Dec. 2025 was $ -0.12 Mil. Chimeric Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chimeric Therapeutics  (OTCPK:CHMMF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chimeric Therapeutics's Interest Expense for the six months ended in Dec. 2025 was $-0.12 Mil. Its Operating Income for the six months ended in Dec. 2025 was $-2.50 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was $0.00 Mil.

Chimeric Therapeutics's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Chimeric Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Chimeric Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Interest Expense Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
-0.01 -0.45 -0.52 -0.22 -0.14

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 0.00 -0.05 -0.08 -0.12
CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chimeric Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.20 Mil mean?
Chimeric Therapeutics (CHMMF) has a Interest Expense of $-0.20 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Interest Expense too high?
Chimeric Therapeutics' current Interest Expense is $-0.20 Mil. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Interest Expense compare to VRTX and REGN?
Chimeric Therapeutics' Interest Expense of $-0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Interest Expense is $-0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Interest Expense of $-0.20 Mil. The current Interest Expense is $-0.20 Mil. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Interest Expense is $-0.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price